Difference between revisions of "Alpelisib (Piqray)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m (→References) |
||
| Line 23: | Line 23: | ||
| − | [[Category:PI3K inhibitors]] | + | [[Category:PI3K alpha inhibitors]] |
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
Revision as of 14:43, 13 December 2020
Mechanism of action
From NCI Drug Dictionary: An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.
Diseases for which it is used
Patient drug information
To be completed
History of changes in FDA indication
- 5/24/2019: Approved in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Also known as
- Code name: BYL719
- Brand name: Piqray